Rapport Therapeutics, Inc. (RAPP)
NASDAQ: RAPP · Real-Time Price · USD
33.74
-1.66 (-4.69%)
At close: Apr 28, 2026, 4:00 PM EDT
33.09
-0.65 (-1.93%)
After-hours: Apr 28, 2026, 5:37 PM EDT
Rapport Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Rapport Therapeutics stock have an average target of 48.5, with a low estimate of 28 and a high estimate of 80. The average target predicts an increase of 43.75% from the current stock price of 33.74.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Rapport Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Reiterates $53 | Strong Buy | Reiterates | $53 | +57.08% | Apr 22, 2026 |
| BTIG | BTIG | Strong Buy Maintains $47 → $53 | Strong Buy | Maintains | $47 → $53 | +57.08% | Mar 11, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $43 → $46 | Buy | Maintains | $43 → $46 | +36.34% | Mar 11, 2026 |
| Wells Fargo | Wells Fargo | Buy Initiates $43 | Buy | Initiates | $43 | +27.45% | Feb 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $34 → $40 | Strong Buy | Maintains | $34 → $40 | +18.55% | Dec 9, 2025 |
Financial Forecast
Revenue This Year
13.60M
Revenue Next Year
n/a
from 13.60M
EPS This Year
-3.41
from -2.86
EPS Next Year
-4.43
from -3.41
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 21.0M | n/a | ||||||
| Avg | 13.6M | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.50 | -3.14 | ||||||
| Avg | -3.41 | -4.43 | ||||||
| Low | -4.48 | -5.55 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.